Benchmark Reiterates Buy on Surgery Partners, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bill Sutherland has reiterated a Buy rating on Surgery Partners (NASDAQ:SGRY) and maintained a $50 price target.
August 26, 2024 | 1:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bill Sutherland reaffirms a Buy rating for Surgery Partners, maintaining a $50 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $50 price target by a reputable analyst suggests confidence in Surgery Partners' future performance, likely leading to positive investor sentiment and potential short-term stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100